Almac Discovery to present at American Association for Cancer Research 2018

Data demonstrates robustness and versatility of proprietary UbiPlex platform for deubiquitinase drug discovery

Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, is pleased to announce it will present 2 posters during this year’s AACR Annual Meeting 2018 in Chicago, April 14-18.

Presentations at the Annual Meeting will cover the latest basic, translational, clinical, and prevention-focused research in the field, including important areas such as early detection, cancer interception, and survivorship in all populations.

The mission of the AACR is to prevent and cure cancer through research, education, communication and collaboration.

Poster details are as follows:

Title: Accessing the cancer DUBome with UbiPlex®: A bespoke drug discovery platform for deubiquitinase enzymes

Session Category: Experimental and Molecular Therapeutics

Session Title: New Targets 1

Session Date and Time: Monday Apr 16, 2018 8:00 AM - 12:00 PM

Location: McCormick Place South, Exhibit Hall A, Poster Section 40

Poster Board Number: 10

Permanent Abstract Number: 1935

Title: Discovery and characterization of highly potent and selective USP7 inhibitors and benchmarking against clinical MDM2 antagonists

Session Category: Experimental and Molecular Therapeutics

Session Title: Novel Targets and Inhibitors

Session Date and Time: Tuesday Apr 17, 2018 1:00 PM - 5:00 PM

Location: McCormick Place South, Exhibit Hall A, Poster Section 39

Poster Board Number: 14

Permanent Abstract Number: 4869

Should you wish to meet with a representative during AACR please contact Martin Wiles, VP Business Development & Licensing – martin.wiles@almacgroup.com.

A copy of both posters will be made available on the Almac Discovery website immediately after the event.

Featured Companies

Almac Group (more information, website)